Cardinal Health Inc. 10-Q Summary: Quarter Ended December 31, 1995
Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter and six months ended December 31, 1995, for Cardinal Health, Inc., a drug wholesaler and distributor. The financial statements have been restated to reflect the pooling-of-interests merger with Medicine Shoppe International, Inc., completed on November 13, 1995. The company operates primarily in the pharmaceutical distribution sector, serving managed care and chain customers.
Key Financial Metrics
| Metric | Q2 1995 | Q2 1994 | 6 Months 1995 | 6 Months 1994 |
|---|---|---|---|---|
| Net Revenues ($000s) | $2,131,627 | $1,999,267 | $4,178,765 | $3,831,395 |
| Gross Margin ($000s) | $136,494 | $123,627 | $266,506 | $237,709 |
| Gross Margin % | 6.40% | 6.18% | 6.38% | 6.20% |
| Operating Earnings ($000s) | $36,995 | $44,803 | $79,790 | $81,527 |
| Net Earnings ($000s) | $18,714 | $24,942 | $42,206 | $44,652 |
| Diluted EPS ($) | $0.38 | $0.51 | $0.86 | $0.93 |
| Cash and Equivalents ($000s) | $27,057 | N/A | $27,057 | N/A |
| Working Capital ($000s) | $660,636 | N/A | $660,636 | N/A |
| Long-Term Obligations ($000s) | $208,690 | N/A | $208,690 | N/A |
Pro Forma Adjustments: Excluding $16.4 million in Medicine Shoppe merger costs, Q2 1995 operating earnings would have been $53.369 million and net earnings $30.514 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7% in Q2 and 9% for the six-month period compared to the prior year, driven by internal growth in wholesaling and new customer acquisitions in managed care and chain sectors.
- Profitability Decline: Reported net earnings decreased 25% in Q2 and 5% for the six-month period. This decline is primarily attributable to a one-time $16.4 million charge for Medicine Shoppe merger costs recorded in Q2.
- Margin Expansion: Gross margin percentage improved to 6.40% in Q2 from 6.18% in the prior year, reflecting expanded merchandising programs, partially offset by lower selling margins due to competitive pressures and high-volume customer mix.
- Liquidity: Working capital increased to $660.6 million from $636.0 million at the end of the prior fiscal year. Cash and equivalents decreased to $27.1 million from $42.5 million due to seasonal inventory purchases and receivables growth.
Outlook, Risks, and Unusual Items
- Merger Activity:
- Medicine Shoppe: Completed November 13, 1995. $16.4 million in merger costs were recorded in Q2, including transaction fees and integration costs.
- Pyxis Corporation: On February 7, 1996, the company announced a definitive agreement to acquire Pyxis in a stock-for-stock merger. Approximately 15.5 million shares are expected to be issued. Completion is expected by early summer 1996.
- Debt Financing: On January 23, 1996, the company sold $150 million of 6% Notes due 2006. Proceeds are intended for general corporate purposes, including debt repayment and working capital.
- Legal Proceedings: The company is a defendant in consolidated antitrust litigation regarding brand name prescription drug pricing. A Judgment Sharing Agreement limits the company's exposure to the lesser of 1% of any judgment or $1 million. Management believes the allegations are without merit and does not expect a material adverse effect.
- Whitmire Merger Costs: Remaining costs associated with the 1994 Whitmire merger are estimated at $3.4 million, expected to be incurred in fiscal 1996.
Investor Verification Checklist
- Verify the pro forma financial impact of the Medicine Shoppe merger excluding the $16.4 million one-time charge.
- Confirm the closing conditions and timeline for the pending Pyxis Corporation acquisition.
- Monitor the status of the Brand Name Prescription Drug Litigation and the enforceability of the Judgment Sharing Agreement.
- Review the utilization of the $150 million in new 6% Notes proceeds, specifically regarding debt reduction versus expansion.
- Assess the sustainability of gross margin improvements given the competitive market environment and high-volume customer mix.